Capitolis Liquid Global Markets LLC bought a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) during the fourth quarter, Holdings Channel reports. The institutional investor bought 878,300 shares of the company’s stock, valued at approximately $61,086,000.
A number of other large investors also recently made changes to their positions in the business. BVF Inc. IL increased its holdings in shares of Structure Therapeutics by 8.6% in the 4th quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock valued at $241,966,000 after purchasing an additional 275,105 shares during the period. ACT Capital Management LLC acquired a new position in shares of Structure Therapeutics in the 4th quarter valued at about $2,678,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Structure Therapeutics in the 4th quarter valued at about $607,000. Burkehill Global Management LP acquired a new position in shares of Structure Therapeutics in the 4th quarter valued at about $4,173,000. Finally, J. Goldman & Co LP acquired a new position in shares of Structure Therapeutics in the 4th quarter valued at about $946,000. Institutional investors and hedge funds own 91.78% of the company’s stock.
Structure Therapeutics Trading Up 4.9%
GPCR stock opened at $45.00 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $15.80 and a 1 year high of $94.90. The company has a fifty day simple moving average of $43.09 and a 200 day simple moving average of $57.53. The firm has a market cap of $3.20 billion, a PE ratio of -51.72 and a beta of -1.35.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on the company. Wall Street Zen downgraded Structure Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. BMO Capital Markets set a $145.00 price objective on shares of Structure Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, March 17th. Leerink Partners reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Finally, HC Wainwright decreased their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $106.75.
View Our Latest Report on GPCR
About Structure Therapeutics
Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.
The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.
Featured Stories
- Five stocks we like better than Structure Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report).
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
